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Abstract
Sexually transmitted infections (STIs), including Chlamydia trachomatis and Neisseria
gonorrhoeae, have reached record high rates in the United States. Sexually transmitted infections
disproportionately affect reproductive-aged males and females 15–44 years of age, who account
for 65% and 42% of the total reported C. trachomatis and N. gonorrhoeae cases, respectively.
These infections are the most common treatable sexually transmitted infections in the United
States. The purpose of this evidence-based practice project was to decrease the rates of
recurrence of STIs in males and females older than 17 years at a private family practice clinic in
Carrollton, Texas, in the Dallas metropolitan area over a period of 6 weeks. An average of 25
confirmed cases of STIs was observed quarterly in the clinic. In January 2022 alone, 20 cases of
confirmed STIs were treated in the clinic, and EPT was offered for each sexual partner with
whom they had had contact within the previous 60 days. Only ten of those 15 patients accepted
EPT, with an acceptance rate of 57%. All twenty-five patients testing positive for infection,
regardless of whether they accepted EPT, were asked to return for an infection check at 8 weeks
after diagnosis to test for the rate infection recurrence. If EPT is found to be effective at reducing
the rates of recurrence of infection in the sexually transmitted infection at the clinic, the
intervention will be used on a permanent basis to reduce rates of recurrence of STI clinic-wide
and in the community.

Keywords: Sexually transmitted infection (STI), gonorrhea, chlamydia trachomatis, partner
notification, partner referral, and EPT.

EXPEDITED PARTNER THERAPY

3

Introduction
The Centers for Disease Control and Prevention (CDC, 2021) estimates that twenty
million new sexually transmitted infections occur each year—almost half among young people
15–24 years of age. The cost of STDs to the U.S. health care system is estimated to be as high as
$16 billion annually. Untreated STDs can lead to serious long-term health consequences,
particularly for adolescent girls and young women. Pelvic inflammatory disease (PID) among
adolescents and young adults can result from untreated sexually transmitted infections (STIs),
such as gonorrhea and chlamydia trachomatis (CT) (Greydanus et al., 2021. The CDC has
estimated that undiagnosed and untreated STDs cause at least 24,000 women in the United States
each year to become infertile.
The CDC, in 2021, estimated that each case of PID, which is caused primarily by CT
and/or Neisseria gonorrhea (GC) costs an average of $3202. Most health care providers advise
their clients with STIs to notify their sex partners. However, the CDC estimates that the
proportion of partners who seek evaluation and treatment in response to patient referral ranges
from 29% to 59%. Studies have demonstrated that re-infection of treated index participants by
untreated partners accounts for 14%–30% of incident bacterial STIs.
In 2019, a total of 616,392 cases of gonorrhea were reported to the CDC, thus making it
the second most common notifiable condition in the United States that year. Rates of reported
gonorrhea have increased 92% since the historic low in 2009. During 2018 to 2019, the overall
rate of reported gonorrhea increased 5.7%. In 2019, a total of 1,808,703 cases of CT infection
were reported to the CDC, making it the most common notifiable condition in the United States
that year. This case count corresponds to a rate of 552.8 cases per 100,000 population,
representing an increase of 2.8% over the rate in 2018. During 2018 to 2019, rates of reported
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chlamydia increased among males and females of all racial and ethnic groups in all regions of the
United States.
Local Issue
Gonorrhea and chlamydia are the most frequently reported bacterial sexually transmitted
infections in the United States. In 2018, 1,758,668 cases of chlamydia were reported to the CDC
from 50 states and the District of Columbia. The CDC estimates that 1.6 million new gonococcal
infections occurred in the United States in 2018, more than half of which occurred among young
people 15–24 years of age. Gonorrhea is the second most reported bacterial sexually transmitted
infection in the United States. Many STI cases are not reported because most people with STIs
are asymptomatic and do not seek testing (CDC 2021).
In 2018, 145,874 cases of chlamydial infection and 46,958 cases of gonorrheal infection
were reported in the Texas Department of State Health Services (2022). The local clinic where
the clinician works treats at least 10–12 patients with STIs monthly, most of whom are patients
returning for the same issue. The clinician believes that it could be secondary to lack of partner
treatment.
Available Knowledge
Most health care providers tell their clients with STIs to notify their sex partners and
encourage them to seek testing and treatment. This scenario is ideal but does not always occur.
Every health care provider has the responsibility to report communicable disease to the local
health department. Health departments tend to focus on partner services for syphilis and HIV and
are less likely to contact and treat partners exposed to gonorrhea and chlamydia. EPT helps
prevent re-infection and reduce transmission of STIs. It saves money by reducing the need to
treat more advanced diseases. Moreover, it allows clinicians to treat more people. EPT may also
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help reduce new HIV infections, because untreated STIs can increase the risk of acquiring and
transmitting HIV (CDC, 2021).
Specific Aims
The clinic protocol currently being used differs from the proposed protocol in that it
allows for partners of the patients to be treated only if they present to the clinic for treatment. For
STI exposed partners to be treated by the clinic, they must return to the STI clinic for their
prescriptions. On most occasions, the partners of the patients do not return to clinic to receive
treatment, thus resulting in repeated STIs and repeated visits of the patients for the same
condition. Expedited partner therapy (EPT), the practice of providing the sexual contacts of
index patients who have tested positive for infection with the same medications, without the
contacts being assessed by a medical provider, has been extensively studied and found to
effectively decrease the rates of reinfection of this common infection (CDC, 2021). Combined
screening and treating of not only patients but also their partners through EPT would reduce the
rates of sexually transmitted infection (CDC, 2021). Changes in the treatment guidelines for STIs
and a reduction of STIs were the intended improvement aims of this intervention project.
Guidelines offer clinical decision support, but policies sometimes require updates.
PICOT Question for the Project
The purpose of this DNP quality improvement (QI) project was to implement an EPT
program that has already been found nationally to reduce rates of recurrence of STI in male and
female patients who test positive for STIs in clinical settings, and to reduce the return rates
among patients’ repeat visits for the same reason.
Immanuel Family Clinic (IFC) is a nurse practitioner-owned primary care clinic that also
encourages walk-in appointments. Reviewing the 10-day reflective practice log indicated that a
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variety of acute and chronic medical conditions require care in this urban primary care practice.
The author identified three opportunities to improve the care provided to the patients. Though
there are many conditions throughout the life span could benefit from QI projects in family
practice. After a meeting with the chair, EPT was selected for this evidence-based project.
According to the review process, the PICOT question guiding the QI project was as follows:
P: Patients 15–45 years of age tested positive for STIs
I: Treated and provided EPT
C: Instead of conventional treatment and partner referral
O: Will have less reinfection rates
T: In a 6-week period

Hence the PICOT question is, can we reduce reinfection of STI among patients aged 15 –
45 years who test positive for sexually transmitted infections, by providing EPT instead of
conventional treatment and partner referral in a period of 6 weeks?
Methods
Context
The PICOT question came from a 10-day reflective practice in the family practice at IFC.
The advanced practice provider formulated the QI proposal, including prescribing EPT to
partners of the patients testing positive for STIs. The QI proposal was submitted and accepted by
the DNP project chair. The IFC administrator approved the project and signed the work letter
allowing the DNP cohort to complete the project at the site. For ethical training in a QI
intervention, the author completed Collaborative Institutional Training Initiative (CITI) training
before applying to the University of Texas at El Paso Institutional Review Board, which
approved the QI project on December 2, 2021, with a letter designating it as not research. The
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project's significance is providing EPT for sexual partners of patients testing positive for STIs, to
enable a more effective intervention to control STIs among the local community. To ensure
patient confidentiality and anonymity in the QI project, all participants and their names were deidentified.
Because of the rising rates of STIs every year, EPT has been approved by the Texas
Department of Health Services (TDHS) to reduce the recurrence and transmission of STIs.
According to the Texas Health Department, the provider can supply clients with oral medications
to give to their partners, prescribe extra doses of medication for partners in a client’s name, or
write prescriptions for clients to deliver to their partners (TDHS, 2021).
Setting
The QI project implementation occurred at IFC in Carrollton, Texas. The project was
started on January 24th and concluded on March 18, 2022. Although patient benefit is the
priority, patients do not often receive the most appropriate treatment. The main concern is that
the partner may not accept treatment or may not return for retesting. Several concerns have been
raised regarding the stigma of being blamed for the STI and the fear of abuse. Traditional partner
notification methods, in which index patients notify their sexual contacts about possible exposure
and need for treatment, have shown to be minimally effective in reducing reinfection rates (CDC,
2015). EPT, the practice of providing the sexual contacts of index patients who tested positive
for infection with the same medications, without assessment of the contacts by a medical
provider, has been studied extensively and found to effectively decrease the rates of reinfection
of this common infection (CDC, 2015). Combined with screening and traditional partner
notification, EPT reduces the rates of CT infection (CDC, 2015).
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Ethical Considerations
The CDC (2022) has addressed disparities in STIs by explaining that poverty, income
inequality, high unemployment rates, and low education are contributing factors. Rates vary
according to gender, age, and ethnicity. The spread of STDs is directly affected by social,
economic, and behavioral factors. Such factors may pose major obstacles to STD prevention
because of their influence on social and sexual networks, access to and provision of care,
willingness to seek care, and social norms regarding sex and sexuality. Among certain vulnerable
populations, historical experience with segregation and discrimination exacerbates the influence
of these factors.
Certain racial and ethnic groups (mainly African American, Hispanic, and American
Indian/Alaska Native populations) have higher rates of STDs than Whites. Race and ethnicity in
the United States are correlated with other determinants of health status, such as poverty, limited
access to health care, fewer attempts to receive medical treatment, and living in communities
with high rates of STDs. According to the CDC, STIs are more prevalent among African
Americans, at rates 5% to 8% higher than those of non-Hispanic White people. Hispanic or
Latino people are one to two times more likely to have STIs than non-Hispanic White people.
CDC, 2021). The CDC has also reported data indicating that young people 15–24 years of age
make up 61% of chlamydia cases and 42% of gonorrhea cases.
However, because most cases of STI at the local clinic have historically existed in the
population over the age of 17, in this study, the age range included patients over the age of 17.
Both female and male patients were included in the study. The goal of the current STI treatment
protocol at the local clinic was to reduce the rate of STI in the population at the local clinic and
community by providing treatment to partners of patients testing positive for STIs. The current
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clinic protocol being used differs from the proposed protocol in that it allows for partners of
index patients to be treated only if they present to the clinic for treatment. For STI exposed
partners to be treated by the clinic, they must return to the STI clinic for their prescriptions. The
study group at the project site is considered a vulnerable population in that they tend to have low
socioeconomic status, to be underserved, and to have a higher percentage of minority ethnic
groups than the surrounding community. To ensure that research was ethical, individual privacy
was maintained by keeping patient involvement from public view. Confidentiality was
maintained by allowing only people directly involved in the project to view the documents and
logs.
EBP Intervention
The CDC, in 2021, stated that “EPT is one of the best tools available for decreasing
gonorrhea and chlamydia rates.” Although EPT has been legal in many states including Texas, it
is underused because providers either do not know about it or are uncomfortable using it (CDC,
2021). This project determined the effects of an evidence-based intervention of EPT comparing
patient outcomes and recurrence of STIs among two groups—those who accepted EPT and those
who did not accept EPT. Patients who met the inclusion criteria were offered EPT. Others were
provided treatment and advised to inform their partners to seek care.
For this evidence-based QI project, each patient over the age of 17 who presented for
treatment of STI after testing positive for chlamydia or gonorrhea at IFC was offered EPT for
each of their heterosexual partners in the prior 60 days. In addition, the patients who tested
positive for STIs (gonorrhea, chlamydia, or both), and who were provided with EPT also
received patient counseling and written treatment instructions for partner(s) (American College
of Obstetricians and Gynecologists, 2020).
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CDC Recommendations for EPT For Gonorrhea and Chlamydia
In cases in which gonorrhea EPT (provision of prescriptions or medications for patients
to take to their sex partners without the health care provider first examining the partners) is
permissible by state law, and the partner is unable or unlikely to seek timely treatment, the
partner may be treated with a single 800 mg dose of cefixime if a chlamydia infection in the
patient has been excluded. If a chlamydia test result has not been documented, the partner may
be treated with a single dose of 800 mg oral cefixime plus 100 mg oral doxycycline two
times/day for 7 days. If adherence with multiday dosing is a considerable concern, 1 g
azithromycin can be considered, although it has lower treatment efficacy among people with
rectal chlamydia. As has always been the case at IFC, medication or prescriptions provided as
part of EPT were accompanied by treatment instructions, appropriate warnings about taking
medications (if the partner is pregnant or has an allergy to the medication), general gonorrhea
health education and counseling, and a statement advising that partners seek personal medical
evaluation, particularly women with symptoms of PID (CDC, 2021).
These index patients were asked how many sexual partners they had had within the past
60 days and were given EPT packs, including prescription and printed educational information,
for as many as three of their sexual partners for the treatment of STI.
For patients who tested positive for chlamydia, a prescription was given for 100 mg
doxycycline twice daily for 7 days. For those who tested positive for gonorrhea, a single dose of
800 mg oral cefixime plus 100 mg oral doxycycline two times/day for 7 days was prescribed for
both the patients and as many as three sexual partners in the prior 3 months. Each patient who
tested positive for STI, whether accepting EPT or not, was asked to return to the clinic in 6
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weeks to be re-tested for STIs. Data were collected and tracked for each of these patients over
this period to assess the percentage of patients accepting EPT for their partners and the effects of
EPT on recurrence rates in this population at the project site.
Patients in the 6 weeks of EPT intervention represented the study group of index patients
followed over the 6 weeks. A test of cure was limited to a 6-week re-testing time. Therefore, the
intervention began in February 2022 and finished in mid-March 2022 to allow for final visits for
testing of cure at 6 weeks post-treatment. Each patient testing positive for STIs was recorded in a
secure database in the computer system at the project site. The provider who offered the EPT to
the positive STI patients entered the data into the system. Within the secure database, each
positive patient’s record was stored, including whether EPT was offered, whether the
intervention was accepted or rejected, and if the intervention was accepted, how many partners
were treated. The student investigator at the project site and the medical assistant were
responsible for maintaining the records of these patients.
The database tracked each patient’s results at their return visit for testing at 6 weeks post
treatment. At the end of the project period, all de-identified data were stored at the project site in
the secure computer database.
Literature Review
A Cochrane database search resulted in an evidence-based literature review to support the
QI project. The selection was difficult, given the extensive evidence-based material available.
The databases searched were PubMed, CINAHL, and Cochrane. In addition, the Google Scholar
search engine was used. Key search terms were sexually transmitted diseases, chlamydia,
gonorrhea, partner notification, partner referral, and EPT. Eight types of study design and six
levels of evidence of the project and guidelines were reviewed. Five studies were compilations of
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systematic reviews of randomized control trials and were level one evidence, according to the
hierarchy developed by Melnyk and Fineout-Overholt (2015). Three articles were single
quantitative randomized controlled trials with level two evidence. Two studies were
observational, and three were cohort studies with level four evidence. Three articles were
reviews of qualitative and/or descriptive quantitative studies and had evidence level five. Six
qualitative studies had level six evidence. One protocol was reviewed along with three articles
that were authoritative opinions and consensus reports on the subject, with level seven evidence.
A total of 13 research articles were evaluated for the effectiveness of EPT as a treatment
for partners of patients positive for GC and/or CT (Buda & Adam, 2021; Gannon-Loew et al.,
2021; Garrett et al., 2017; Jamison et al., 2019; Layton et al., 2021).
Most studies found a statistically significant difference in the rates of recurrence of GC
and CT when partners were treated with EPT but found that the recurrence rates were lower
when EPT was used to treat partners of patients positive for GC. One study noted that EPT’s
costs and efficacy make it a cost-effective alternative to treat partners (Cameron et al., 2009).
EPT has been found to be a most reliable option for partners who are unwilling or unable to seek
treatment (Hogben, 2007).
One qualitative study regarding barriers and enablers of PDPT has largely focused on the
views of healthcare providers. In that study, the researchers sought to investigate the views of
young people (as potential health consumers) regarding EPT for chlamydia (Layton et al., 2021).
A pilot study was conducted to determine whether female adolescents with CT accept
and deliver EPT to male sexual partners, and whether this practice is associated with decreased
CT reinfection rates at 3 and 6 months. Additionally, results at 3 months revealed high rates of
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reinfection, but the implications of these findings are limited by the small sample size (Vacca et
al., 2019).
An anonymous cross-sectional survey was administered to a convenience sample of 312
youths 15–24 years of age presenting to a youth-focused community health center in Ajax, ON.
The survey concluded that EPT acceptance over traditional treatment has more significant
potential to reach youths engaging in higher-risk sexual behavior
(Vandermorris et al., 2019).
A randomized control study conducted in South Africa has evaluated EPT’s effectiveness
in treating STI among women diagnosed with STI. A total of 267 women, with a median age of
23 years (IQR 21–27), were screened, and 63 (23.6%) were diagnosed with an STI. Of these,
62/63 (98.4%) were offered, and 54/62 (87.1%) accepted, EPT for their regular partner. Of the
first 53 women completing follow-up, reinfection rates were lower among women receiving EPT
than those who did not accept EPT (Garrett et al., 2017).
A prospective study was conducted from September 2016 through June 2018 with
approximately 100 individuals diagnosed with CT and NG infections receiving care at the three
University of Michigan clinical sites, including the Regional Alliance for Healthy Schools
school-based clinics. In trials of mostly men diagnosed in public health or STI clinics with
chlamydia or gonorrhea, EPT was found to be more effective in decreasing reinfection than
simple patient referral (Buda & Adam, 2021).
Another study has been conducted to evaluate EPT in female adolescents by studying the
acceptance and the effects on reinfection rates of sexually transmitted disease. It evaluated EPT
acceptance and compared reinfection rates (positive test 1–6 months after initial infection) in the
pre-EPT versus post-EPT cohorts, and EPT acceptance. The results were consistent with a
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significant reduction in STI among patients who accepted and were treated with EPT (GannonLoew et al., 2021).
Another pilot study has been conducted to determine whether female adolescents with CT
accept and deliver EPT to male sexual partners, and whether this practice is associated with
decreased CT reinfection rates at 3 and 6 months. The study results have encouragingly indicated
that acceptance of EPT is associated with reductions in CT reinfection at 3 months (Vacca et al.,
2019).
One qualitative study exploring patients’ acceptance of EPT has found that patients
prefer other methods for treating partners, such as partner referral and bringing partners to the
clinic for treatment (Buchsbaum et al., 2014). Two other reviewed studies indicated a 50%–55%
acceptance rate among index patients for treatment of their partners (Mickiewicz et al., 2012;
Vaidya et al., 2014). Patients were more likely to accept EPT for their partners if they had
symptoms at the time of the initial appointment, if they had more clinic appointments, and if the
medical provider was male (Vaidya et al., 2014). They were unlikely to accept EPT if their
partner was in clinical settings with them that day or if their native language was not English
(Vaidya et al., 2014).
Methods of Evaluation
Theory
Protection motivation theory (PMT) is used to evaluate health behavior as it relates to
beliefs about a specific health threats and coping strategies pertaining to a prescribed action or
treatment by a health care provider (Rogers, 1975). In a study implementing EPT in a population
of mostly young men and women, PMT can explain the variations in health decisions in this
population. PMT helps healthcare providers address individual fears associated with
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vulnerability and susceptibility to CT. The use of PMT in this EBP project also assisted in
evaluating individuals’ coping processes, involving beliefs relating to EPT’s efficacy, selfefficacy using EPT, and the associated costs of using EPT as a supplemental treatment for CT
infection (Maddux & Rogers, 1983).
PMT encompasses two major theoretical concepts, the threat-appraisal process and the
coping appraisal process, both of which are cognitive mediating processes (Rogers, 1975). The
threat appraisal process evaluates maladaptive behavior as it relates to intrinsic and extrinsic
rewards, a person’s perception of the severity of a threat, and the perceived probability of the
threat’s occurrence (Rogers, 1975). The coping-appraisal process evaluates adaptive responses or
one’s ability to cope by addressing response efficacy, self-efficacy, and beliefs relating to the
costs involved in a chosen response (Rogers, 1975). These concepts were evaluated by the
student investigator to change patients’ maladaptive responses to a fear or a threat into adaptive
responses aimed at protection motivation (Floyd et al., 2000).
PMT is a higher-level theory in which providers use a persuasion technique to instill fear
relating to a particular health threat with the intention of controlling and/or altering the response
by the patient (Rogers, 1975). This middle-range theory specifically addresses health beliefs and
people’s actions associated with their health beliefs as well as concepts easy to operationally
define (McEwen & Wills, 2014). PMT has been validated as a reliable framework for studies on
reducing alcohol consumption, smoking cessation, STI prevention, and chronic diseases. It is
applicable to any study on a defined health threat with an effective response or treatment that can
be implemented by a person (Floyd et al., 2000).
The Plan-Do-Study-Act (PDSA) was selected as the QI model. PDSA provide four cycles
for analysis or the intended change on each of the patients included in the QI project (Institute
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for Healthcare Improvement, 2020). The Plan phase is the evidence-based intervention itself.
The Do phase involves reviewing and agreeing on the plan of treatment with the patients,
including drug education, therapeutic benefit and adverse effects, and patient responsibility to
inform sexual partners and return for follow-up appointments. In the real-world data from the QI
project, the Study phase of the PDSA included analysis of patients who tested positive for STI
(gonorrhea and or chlamydia), discussion of treatment options, EPT, adverse effects, and
retesting for the STI in 6 weeks. The data indicated the effectiveness of clinical care in the DNP
cohort, through analysis of individual patient clinical characteristics, such as patient access to
therapy and cost. In the Act phase, an ongoing adjustment in the real-world evidence of complete
cycles provided opportunities to identify modifiable factors, such as creating a clinical protocol
to support future adherence.
The Iowa Model of Evidence-Based Practice to Promote Quality Care (Melnyk &
Fineout-Overholt, 2015) is the model that best aligns with this project. It consists of six steps.
Step one involves assessing the need for changes or any problems that trigger the need for
clinical change and includes stakeholders in this step (Gawlinski & Rutledge, 2008). Step two
examines the best evidence for the project, and step three involves critically analyzing that
evidence. Step four is the working phase of the project, in which the design of the project is
developed. Implementation of the evidence-based QI project and evaluation of the pilot study is
performed in step five, and in step six, a plan for maintaining change is developed. The project
was implemented on a short term period of 6 weeks, and the outcomes were favorable.
Project Design
Because this project was aimed at determining the effects of an evidence-based
intervention of EPT on patient outcomes and recurrence rates in one cohort, a comparative
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design was necessary. Patients who met the inclusion criteria and tested positive for STIs were
offered EPT Phone calls were made at the end of week 2 to confirm that the treatment was
completed among both groups. All patients responded except for one, for whom a voicemail was
left to contact the clinic. Outcome data were gathered for patients who accepted and did not
accept the EPT intervention in a 6-week period. Urine was sent for nucleic acid amplification
testing (NAAT). NAAT is the preferred method for detecting chlamydia and gonorrhea
infections. This test detects the genetic material (DNA or RNA) of CT or gonorrhea. It can be
performed on a urine sample or swab of fluid taken from a site of potential infection, such as the
urethra, vagina, rectum, or eye. The NAAT tests for viable and non-viable organisms and can
detect a single copy of DNA or RNA. Because this test is sensitive, less invasive methods for
sample collection, such as urine samples, can be used to detect infection. This test has greater
than 90% sensitivity or reliability and greater than 99% specificity or validity. The sensitivity
and specificity are greater than those of other culture tests for CT. Most companies selling the
test have reported no false positive results (Rapp et al., 2014).
The NAAT was performed by testing patients’ urine samples. At the end of 6 weeks,
patients returning for the test of cure visits had their results stored in the secure database. The
rates of recurrence were calculated and compared between index patients accepting and not
accepting EPT.
Analysis
The QI project implementation started on January 24, 2022. A total of 16 patients with
STIs were seen at the clinic in the 5 weeks. Among them, eight were positive for chlamydia, and
three were positive for gonorrhea. The remaining five were positive for syphilis or herpes.
Therefore, only 11 patients who tested positive for chlamydia and gonorrhea qualified for the
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study. The study phase of the PDSA QI model was used in this analysis. Each patient included in
the project was educated about the benefits of EPT and how it works in detail. The patients who
accepted the EPT were given materials and prescriptions for their partners in the prior 3 months
for the STI, as well as reading material from the CDC website.
Internal validity was controlled for in this project by using the same test, (NAAT) on
urine samples, for each patient. This test is the method of choice for measuring results for CT
and is an accurate, valid test. The project population was male and female patients over 17 years
of age. Because the population in the family practice clinic at the project site comprised males
and females of all ages, external validity or generalizability can be assured in the findings of this
project. All patients meeting the inclusion criteria were offered EPT. Those patients who
accepted EPT (the test group) were compared with those who did not accept EPT (the control
group) at 6 weeks for reoccurrence of infection. The comparison between the test group and the
control group, although not randomly grouped, enhanced the validity and therefore the
significance of the findings.
Measured Outcomes
Outcome data were gathered on patients who accepted and did not accept the EPT
intervention. At the end of the 6 weeks, patients returning for test of cure visits had their results
stored in the secure database, and rates of recurrence were calculated and compared between
index patients accepting and those not accepting EPT. The percentage of patients accepting EPT
in this pilot study was compared with the percentage of patients accepting EPT in previous
studies, to determine the program’s effectiveness in terms of acceptance rates by the index
patients. The uptake of EPT by the infected index patients was measured, thus providing
information on the recurrence rates of STIs. In addition, the study measured the rates of
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recurrence of STI at 6-week follow-up visits for each patient who tested positive for infection at
the initial encounter and then accepted EPT. The infection rates in patients accepting and not
accepting EPT were compared at the 6-week visits. These measurements indicated the total
number of reoccurrences of infection in the sub-group of patients accepting EPT compared with
the sub-group not accepting EPT, thereby allowing for measurement of the intervention’s
effectiveness.
Outcome Data
The desired outcome from this evidence-based QI project was to reduce rates of
recurrence of CT infection by initially implementing a program that has been shown in prior
studies to reduce rates of recurrence. Therefore, the required initial measured outcome of
importance was the uptake of that intervention. That outcome was easily measured as the number
of patients seen in the clinics who tested positive and accepted the EPT intervention. The
percentage of index patients accepting EPT compared with historical data indicated the possible
effects of EPT on the recurrence rates.
Sixteen patients presented to the clinic for STI screening over the 2-week period. Among
them, eight patients tested positive for CT, three patients tested positive for GC, and five tested
positive for other STIs, such as syphilis or herpes. Those five cases were excluded from
participation in the project. Of the 11 positive cases, seven patients accepted EPT, and four did
not accept EPT because they indicated that they did not have any way of contacting their
partners. Two of those seven patients accepted two prescriptions of EPT because they had had
contact with multiple partners. The percentage of patients accepting EPT who were offered EPT
by program inclusion criteria was 63%. Those index patients not accepting EPT indicated
reasons for not accepting the method including “my partner knew already,” “they have an
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appointment for treatment already,” “they are not in contact with me anymore,” and “they want
to go to their own doctor” (personal communication, February 2022).
Figure 1
Pre intervention
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Figure 2
Post intervention
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Interpretation
At the end of 6 weeks, all eleven patients included in the study were retested during the
cure visit, and four positive cases were found (two from the EPT group and two from the nonEPT group). The percentage recurrence in the population of index patients who accepted EPT
(seven patients) compared with the remaining four patients who were positive for STIs and did
not accept the intervention. These data are consistent with a recurrence rate of 28.6% among the
group that accepted EPT and the rate of reoccurrence of STIs is higher, at 75%. However, the
purpose of this project was to implement EPT as an effective treatment modality for STI
treatment. The 63% acceptance rate indicated that patients are likely to accept the intervention,
as compared with the acceptance rate between 50% and 55% in historical data, thus indicating
that this was an effective intervention at the project site. The lower reoccurrence rate of 28.6%
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supports adopting a policy at the clinic in which every patient would be offered with EPT as part
of treatment for STIs, particularly chlamydia and gonorrhea.
Project Strengths
The CDC, in 2021, confirmed that EPT is effective in the effective treatment of STIs and
reducing the rate of reinfection with STIs. “It is crystal clear that the people really need it,”
stated one premedical student at the project site (personal communication, March 2022). Based
on initial contact, the staff at the project site clearly supported offering EPT to patients positive
for STIs, and they continued to advocate for the intervention after having offered it to their
patients for only 6 weeks. Because the medical assistants were the initial point of contact with
patients, their buy-in would be important to ensure the longevity of the program.

Because the nurses run the STI clinic by using protocols for testing and treatment, their
agreeing with the need for this program and seeing the success with patients willing to be
educated and to accept EPT were crucial. All employees were satisfied with the outcome of the
QI project and asked questions about including GC treatment in the EPT protocol. They will be
the team advocating for the continued use of this modality at the clinics with the leadership team,
which has been supportive of EPT use from the onset. With measured success and support from
staff, leadership should remain content with the use of EPT.
Limitations
The DNP cohort believed that the brief period time was the main limitation of this QI
project. Additional limitations include the small group of patients seen during the 6 weeks, and
that the EPT, an evidence-based practice treatment modality, was limited to small group of
patients in a brief period. The limitations in the reliability of this EBP project are the short
timeframe and small number of participants compared with those in benchmark studies.

23

EXPEDITED PARTNER THERAPY
Conclusion

Success in this evidence-based QI project was evident in the percentage of patients who
accepted EPT and the low rates of recurrence after offering of EPT. Before program
implementation, how receptive the index patients would be toward a new intervention for
treating STI was uncertain. However, the high percentage of patients willing to try EPT, and the
positive results of the intervention indicate the success of this evidence-based treatment modality
at the project site. Patients were also verbally positive in their responses to the medical assistants
who provided them with EPT materials (personal communication, March 2022). In addition, the
provider and the staff liked being able to offer EPT to patients and were certain that they would
continue offering EPT soon.
Although this was an evidence-based practice pilot project, EPT was found to be an
effective method to notify and treat partners and reduce rates of recurrence, as compared with
traditional partner notification methods, at IFC. In prior studies, screening and treating patients
and their partners with EPT has empirically been found to save health care costs through
decreased recurrence rates and sequelae of infections. EPT is therefore an efficient, effective, and
patient accepted means of reducing STI recurrence rates in the local community.
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